0000885590-15-000025.txt : 20150417
0000885590-15-000025.hdr.sgml : 20150417
20150417172817
ACCESSION NUMBER: 0000885590-15-000025
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150415
FILED AS OF DATE: 20150417
DATE AS OF CHANGE: 20150417
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Valeant Pharmaceuticals International, Inc.
CENTRAL INDEX KEY: 0000885590
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2150 ST. ELZEAR BLVD. WEST
STREET 2: LAVAL
CITY: QUEBEC
STATE: A8
ZIP: H7L 4A8
BUSINESS PHONE: 514-744-6792
MAIL ADDRESS:
STREET 1: 2150 ST. ELZEAR BLVD. WEST
STREET 2: LAVAL
CITY: QUEBEC
STATE: A8
ZIP: H7L 4A8
FORMER COMPANY:
FORMER CONFORMED NAME: BIOVAIL Corp
DATE OF NAME CHANGE: 20100416
FORMER COMPANY:
FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL
DATE OF NAME CHANGE: 19960522
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mirovsky Pavel
CENTRAL INDEX KEY: 0001577638
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14956
FILM NUMBER: 15779090
MAIL ADDRESS:
STREET 1: 2150 ST. ELZEAR BLVD. WEST
CITY: LAVAL
STATE: A8
ZIP: H7L 4A8
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2015-04-15
0
0000885590
Valeant Pharmaceuticals International, Inc.
VRX
0001577638
Mirovsky Pavel
2150 ST. ELZEAR BLVD. WEST
LAVAL
A8
H7L 4A8
QUEBEC, CANADA
0
1
0
0
President, EMENA
Common Stock, no par value
2015-04-15
4
M
0
24175
0
A
34175
D
Restricted Share Units
2015-04-15
4
M
0
24175
0
D
Common Stock
48350
24175
D
This represents the number of units vested on the performance-based RSUs ("PSUs") that were previously reported on the original Form 4. The initial grant was reported to vest based on total shareholder return (TSR) between a price of $108.97 starting on January 9, 2014 and the average stock price for the 20 trading days starting on each measurement dates: 25% on October 9, 2016, 50% on January 9, 2017 and 25% on April 9, 2017. Unit vesting is contingent on TSR performance between 10% and 30% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels. The PSU award may still payout two times grant value.
Represents the maximum number of Common Shares that may be issued under the RSU award.
by: Nicholas Zanoni for Pavel Mirovsky
2015-04-17